Olmesartan/Amlodipine Eg (Amlodipine, Olmesartan)

Olmesartan and amlodipine, the active ingredients in Olmesartan/Amlodipine EG, are a calcium‑channel blocker and an angiotensin II receptor blocker presented as a fixed‑dose oral tablet for once‑daily use. They are indicated for the treatment of hypertension in adult patients, helping to lower systolic and diastolic blood pressure and reduce cardiovascular risk.

GNH USA supplies Olmesartan/Amlodipine EG as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine EG is indicated for the management of hypertension, acting on the renin‑angiotensin system and vascular smooth‑muscle tone.

- Hypertension: provides sustained blood‑pressure reduction and improves cardiovascular outcomes. - Hypertension in patients requiring combination therapy: offers convenient dual‑mechanism control when monotherapy is insufficient. - Hypertension with comorbidities such as diabetes: assists in achieving target blood pressure while minimizing metabolic impact.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Peripheral edema: swelling of the ankles or lower legs. - Flushing: transient warmth and redness of the skin. - Dizziness: sensation of light‑headedness, especially when standing. - Fatigue: general feeling of tiredness. - Palpitations: awareness of heartbeats.

Serious or Rare Side Effects: - Hypotension: marked drop in blood pressure causing faintness. - Angioedema: swelling of face, lips, tongue, or throat requiring urgent care. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Severe allergic reaction: rash, itching, or anaphylaxis. - Myocardial infarction: rare occurrence of heart attack. - Renal impairment: worsening kidney function in susceptible individuals.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function assessment: adjust dosing in patients with impaired kidney function. - Hepatic impairment: use with caution in moderate to severe liver disease. - Pregnancy: avoid use; teratogenic risk associated with angiotensin receptor blockers. - Elderly patients: start at lower dose and monitor for orthostatic effects. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/Amlodipine EG may interact with several medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin): increase amlodipine exposure. - Concurrent antihypertensives: risk of additive hypotension. - Potassium‑sparing diuretics or supplements with ARBs: may cause hyperkalaemia. - High‑dose simvastatin: increased risk of myopathy when combined with amlodipine. - Lithium: elevated lithium levels and toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Diuretics: can potentiate electrolyte disturbances. - CYP3A4 inducers (e.g., rifampin): reduce amlodipine concentrations. - Grapefruit juice: may raise amlodipine plasma levels. - Antacids containing aluminum or magnesium: may affect absorption of olmesartan.